Legal & General Group’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.59M | Buy |
314,785
+66,803
| +27% | +$338K | ﹤0.01% | 2053 |
|
|
2025
Q1 | $1.31M | Sell |
247,982
-5,444
| -2% | -$28.8K | ﹤0.01% | 2080 |
|
|
2024
Q4 | $1.71M | Buy |
253,426
+67,953
| +37% | +$459K | ﹤0.01% | 2040 |
|
|
2024
Q3 | $1.22M | Buy |
185,473
+4,330
| +2% | +$28.5K | ﹤0.01% | 2164 |
|
|
2024
Q2 | $1.36M | Buy |
181,143
+29,404
| +19% | +$221K | ﹤0.01% | 2094 |
|
|
2024
Q1 | $1.51M | Buy |
151,739
+22,118
| +17% | +$221K | ﹤0.01% | 2042 |
|
|
2023
Q4 | $1.28M | Buy |
129,621
+11,571
| +10% | +$114K | ﹤0.01% | 2117 |
|
|
2023
Q3 | $903K | Buy |
118,050
+6,465
| +6% | +$49.5K | ﹤0.01% | 2219 |
|
|
2023
Q2 | $834K | Buy |
111,585
+11,035
| +11% | +$82.4K | ﹤0.01% | 2287 |
|
|
2023
Q1 | $671K | Buy |
100,550
+6,580
| +7% | +$43.9K | ﹤0.01% | 2249 |
|
|
2022
Q4 | $725K | Buy |
93,970
+4,463
| +5% | +$34.4K | ﹤0.01% | 2240 |
|
|
2022
Q3 | $952K | Sell |
89,507
-22,830
| -20% | -$243K | ﹤0.01% | 2162 |
|
|
2022
Q2 | $914K | Buy |
112,337
+47,649
| +74% | +$388K | ﹤0.01% | 2194 |
|
|
2022
Q1 | $463K | Buy |
64,688
+43,935
| +212% | +$314K | ﹤0.01% | 2413 |
|
|
2021
Q4 | $355K | Buy |
20,753
+18,047
| +667% | +$309K | ﹤0.01% | 2523 |
|
|
2021
Q3 | $62K | Buy |
2,706
+655
| +32% | +$15K | ﹤0.01% | 2929 |
|
|
2021
Q2 | $75K | Buy |
+2,051
| New | +$75K | ﹤0.01% | 2821 |
|